Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1991 Jul;117(Suppl 4):S224–S227. doi: 10.1007/BF01613232

Ifosfamide and ACNU in experimental allogeneic bone marrow transplantation

W Gassmann 1,✉, A Erbersdobler 1, L Uharek 1, B Glass 1, H Löffler 1, W Mueller-Ruchholtz 1
PMCID: PMC12201212  PMID: 1795012

Abstract

We have tested ifosfamide and ACNU for their effectiveness in preventing graft rejection following allogeneic bone marrow transplantation. The engraftment-promoting potency of both was compared to that of the standard agent cyclophosphamide. LEW rats received a lethal dose (35 mg/kg) of busulfan followed by injection of 1×108 (CAP×LEW) F1 marrow cells, which are unable to induce a graft vs host reaction in LEW recipients. Rejection of the marrow graft was assessed by monitoring haematocrit and granulocyte count either until death of the animal or until day 80. Surviving animals received a donor-type skin graft to confirm the persistence of allogeneic haematopoiesis. Because of its weak immunosuppressive properties, busulfan by itself is unable to allow engraftment of allogeneic marrow. Therefore, ifosfamide and ACNU and cyclophosphamide as the standard agent could be tested for their capacity to prevent marrow graft rejection. The following rejection rates were observed: cyclophosphamide: 30 mg/ kg 100%, 60 mg/kg 60%, 90 mg/kg 20%, 120 mg/kg and 180 mg/kg 0%; ACNU: 3, 5, 7, and 10 mg/kg 100%, 15 mg/kg 45%, 20 and 30 mg/kg 0%; ifosfamide: 60–120 mg/kg 100%, 180 mg/kg 68%, 240 and 360 mg/kg 0%. Thus, 240 mg/kg ifosfamide or 20 mg/kg ACNU is nearly equivalent to the standard dose of 120 mg/kg cyclophosphamide in engraftment-promoting potency in allogeneic bone marrow transplantation.

Key words: Bone marrow transplantation, Ifosfamide, Cyclophosphamide, ACNU, Busulfan

Footnotes

Supported by a grant from Heinz and Gudrun Bauer, Hamburg/ FRG, in memory of their son Hendrik

References

  1. Antmann KH, Elias A, Ryan L (1990) Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol 17 [Suppl 4]:68–73 [PubMed] [Google Scholar]
  2. Davies SM, Pearson ADJ, Craft AW (1989) Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol 24 [Suppl]:S8-S10 [DOI] [PubMed] [Google Scholar]
  3. Elias A, Eder JP, Ayash L, Wheeler C, Deary J, Weissman L, Schryber S, Critchlow J, Hunt M, Schnipper L, Frei E III, Antman K (1990) A phase I study of ifosfamide (IFX) and carboplatin (Cb) with bone marrow transplantation. J Cancer Res Clin Oncol 116 [Suppl Part II]:822 [Google Scholar]
  4. Floersheim GL, Elson LA (1961) Wiederherstellung der Hämatopoese nach letaler Dosis von Dimethyl-Myleran durch isologe Knochenmarktransplantation bei Mäusen. Versuche zur Beeinflussung der Intoleranz gegenüber homologem Knochenmark durch 6-Mercaptopurin, Aminochlorambucil and Cortison. Acta Haematol 26:233–245 [DOI] [PubMed] [Google Scholar]
  5. Gassmann W, Uharek L, Wottge H-U, Schmitz N, Loeffler H, Mueller-Ruchholtz W (1988) Comparison of cyclophosphamide, cytarabine, and etoposide as immuno-suppressive agents prior to allogeneic bone marrow transplantation. Blood 72:1574–1579 [PubMed] [Google Scholar]
  6. Gassmann W, Uharek L, Erbersdobler A, Wottge H-U, Loeffler H, Mueller-Ruchholtz W (1990) Comparison of the engraftment promoting potential of high-dose cytostatic agents in allogeneic bone marrow transplantation. In: Freund M, Link H, Weile K (eds) Cytokines in hemopoiesis, oncology, and AIDS. Springer, Berlin Heidelberg New York, pp 365–372 [Google Scholar]
  7. Gassmann W, Uharek L, Erbersdobler A, Glass B, Wottge H-U, Schmitz N, Loeffler H, Mueller-Ruchholtz W (1991) High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potential. Br J Haematol 78:310–318 [DOI] [PubMed] [Google Scholar]
  8. Harada M, Yoshida T, Funada H, Ishino C, Kodo H, Mori T, Matsue K, Shiobaa S, Odaka K, Ohtake S, Teshima H, Kondo K, Yamamura M, Nakao S, Ueda M, Nakamura S, Hattori K for the Kanazawa University Bone Marrow Transplant Team (1982) Combined-modality therapy and autologous bone marrow transplantation in the treatment of advanced non-Hodgkin's lymphoma and solid tumor: The Kanazawa experience. Transplant Proc 14:733–737 [PubMed] [Google Scholar]
  9. Harada M, Yoshida T, Funada H, Hattori K-I, Kanazawa University Bone marrow Transplant Team (1984) Clinical trial of intensive therapy and autologous bone marrow transplantation in the treatment of malignant diseases. Jpn J Clin Oncol 14 [Suppl 1]:543–552 [PubMed] [Google Scholar]
  10. Mizushima Y, Morikage T, Sasaki K, Yano S (1989) Most effective route of administration and utilization of high-dose chemotherapy with bone marrow transplantation in rats. Cancer Res 49:2561–2566 [PubMed] [Google Scholar]
  11. Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K, Skeggs D, Morgan H, Lord J, Blacklock HA, Hoffbrand AV, Apperley JF, Goldman JM, Burnett A, Gribben J, Alcorn M, Pearson C, McVickers I, Hann IM, Reid C, Wardle D, Gravett PJ, Bacigalupo A, Robertson AG (1986) Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 63:221–230 [DOI] [PubMed] [Google Scholar]
  12. Sakoda K, Uozumi T, Kawamoto K, Fujioka Y, Hasada J, Hatayama T, Nakahara T (1989) Responses of pineocytoma to radiation therapy and chemotherapy-report of two cases. Neurol Med Chir 29:825–829 [DOI] [PubMed] [Google Scholar]
  13. Santos GW, Tutschka PJ (1974a) Effect of busulfan on antibody production and skin allograft survival in the rat. J Natl Cancer Inst 53:1775–1780 [PubMed] [Google Scholar]
  14. Santos GW, Tutschka PJ (1974b) Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst 53:1781–1785 [PubMed] [Google Scholar]
  15. Schwartzmann E, Scopinaro M, Angueyra N (1989) Phase II study of ifosfamide as a single drug for relapsed paediatric patients. Cancer Chemother Pharmacol 24 [Suppl]:S11-S12 [DOI] [PubMed] [Google Scholar]
  16. Storb R (1987) Critical issues in bone marrow transplantation. Transplant Proc 19:2774–2781 [PubMed] [Google Scholar]
  17. Tutschka PJ, Santos GW (1975) Bone marrow transplantation in the busulfan-treated rat. Transplantation 20:101–106 [DOI] [PubMed] [Google Scholar]
  18. Uharek L, Gassmann W, Fleischhauer D, Wottge H-U, Loeffler H, Mueller-Ruchholtz W (1989) Comparison of the immunosuppressive agents for prevention of graft rejection in allogeneic bone marrow transplantation. Transplant Proc 21:3042–3044 [PubMed] [Google Scholar]
  19. Uharek L, Glass B, Gassmann W, Loeffler H, Mueller-Ruchholt W (1990) Graft rejection after allogeneic bone marrow transplantation: the impact of marrow cell dose and GVHR. Exp Hematol 18:652 [Google Scholar]
  20. Zwaan FE (1987) The use of donors other than HLA-identical siblings in bone marrow transplantation. In: Gale RP, Champlin R (eds) Progress in bone marrow transplantation. Liss, New York, pp 677–687 [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES